1020174-04-2

Basic information

• Product Name: 1-Methyl-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• Synonyms: 1H-Pyrazole, 1-Methyl-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;1-Methylpyrazol-3-yl-4,4,5,5-tetraMethyl-[1,3,2]dioxaborolane;1-Methyl-3-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-Methylpyrazol-3-yl-boronic acid pinacol ester;1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole;(1-METHYL-1H-PYRAZOL-3-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 1020174-04-2
• Molecular Formula: C₁₀H₁₇BN₂O₂
• Molecular Weight: 208.06518
• Mol File: 1020174-04-2.mol

Chemical Properties

• Boiling Point: 308.328 °C at 760 mmHg
• Flash Point: 140.272 °C
• Appearance: /
• Density: 1.05
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 2.23±0.10(Predicted)
• CAS DataBase Reference: 1-Methyl-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1020174-04-2)
• EPA Substance Registry System: 1-Methyl-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1020174-04-2)

Safety Data

• Hazardous Substances Data: 1020174-04-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a synthetic reagent for the production of quinoxaline derivatives or heterocyclylamine derivatives. These derivatives have potential applications as inhibitors of PI3 kinase, an enzyme that plays a crucial role in cellular processes such as growth, survival, and metabolism. Inhibition of PI3 kinase has been explored as a therapeutic strategy for various diseases, including cancer.
Used in Research and Development:
In addition to its pharmaceutical applications, 1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is also utilized in research and development settings. It serves as a valuable building block for the synthesis of novel compounds with potential applications in various fields, such as medicinal chemistry, materials science, and chemical biology. Researchers can use 1-Methyl-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole to explore new chemical reactions and develop innovative strategies for the synthesis of complex molecules with specific biological activities.

Upstream product

• 844501-71-9 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole 
• 74-88-4 methyl iodide 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 92525-10-5 3-iodine-1-methyl-1H-pyrazole 
• 151049-87-5 3-bromo-1-methyl-1H-pyrazole 
• 73183-34-3 bis(pinacol)diborane 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 

Downstream Products

• 1225278-37-4 5-chloro-2-fluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline 
• 1581258-02-7 N-(2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl)-6-(1-methyl-1H-pyrazol-3-yl)pyrazin-2-amine 
• 1426530-94-0 4-fluoro-3-{[7-(2-methyl-2H-pyrazol-3-yl)-imidazo[1,2-a]pyridine-3-carbonyl]-amino}-benzoic acid 
• 1426530-82-6 N-(5-((2-(2,6-cis-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1432513-62-6 C₂₁H₁₇FN₆O₄S₂ 
• 1426133-19-8 methyl 3-(3-(4-methyl-3-(7-(1-methyl-1H-pyrazol-3-yl)imidazo[1,2-a]pyridine-3-carboxamido)phenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 

Relevant articles and documents

TYK-2 INHIBITOR

Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating a disease associated with the undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Synthetic method of 1-methyl-1H-pyrazole-3-boronic acid pinacol ester

The invention discloses a synthetic method of 1-methyl-1H-pyrazole-3-boronic acid pinacol ester. The method comprises the following steps: step 1, 3-iodine-1-methyl-1H-pyrazole is synthesized from N-methyl-3-aminopyrazole through a diazotization reaction; step 2, 3-iodine-1-methyl-1H-pyrazole prepared in the step 1 is taken as a raw material of reaction, n-butyllithium is taken as a base, isopropoxyboronic acid pinacol ester is taken as a boronizing reagent, and 1-methyl-1H-pyrazole-3-boronic acid pinacol ester is obtained through synthesis. 1-methyl-1H-pyrazole-3-boronic acid pinacol ester with high purity is prepared with a simpler process, lower cost and higher yield. After deep analysis of a target product, N-methyl-3-aminopyrazole is taken as the raw material, iodine with higher activity is prepared through direct diazotization, and production of isomers during methyl introduction in the prior art is avoided, so that the yield is increased greatly and the purification difficulty is reduced greatly.

KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF

This application relates to ketone compounds of imidazoles, pharmaceutically acceptable salts, solvents, polymorphs or prodrugs thereof, and further relates to pharmaceutical combinations comprising the foregoing substances and uses for preventing and treating protein kinase related diseases such as cancer, metabolic diseases, and cardiovascular diseases.

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

HETARYLAMINONAPHTHYRIDINES

Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.